Trial Outcomes & Findings for PillCam™ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon (NCT NCT00604162)

NCT ID: NCT00604162

Last Updated: 2019-08-01

Results Overview

The number of participants that completed the capsule endoscopy procedure with video images of the entire colon that could be read by a clinician, or subsequently had a full colonoscopy with visualization by a different clinician. The number of successful procedures of each type are reported.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

332 participants

Primary outcome timeframe

1 day

Results posted on

2019-08-01

Participant Flow

8 Hospital sites

Four patients withdrew before completing the study documents and were not included in the analysis.An additional 8 patients were not included in the analysis of the accuracy of polyp detection.

Participant milestones

Participant milestones
Measure
Colon Capsule Endoscopy, Then Standard Colonoscopy
Capsule endoscopy was ingested following colon preparation without colon insufflation or sedation.The purpose was to detect patients with polyps equal or larger than 6mm. Patients subsequently had standard colonoscopy as "gold standard" comparison.
Overall Study
STARTED
332
Overall Study
COMPLETED
328
Overall Study
NOT COMPLETED
4

Reasons for withdrawal

Reasons for withdrawal
Measure
Colon Capsule Endoscopy, Then Standard Colonoscopy
Capsule endoscopy was ingested following colon preparation without colon insufflation or sedation.The purpose was to detect patients with polyps equal or larger than 6mm. Patients subsequently had standard colonoscopy as "gold standard" comparison.
Overall Study
Physician Decision
3
Overall Study
Withdrawal by Subject
1

Baseline Characteristics

PillCam™ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Colon Capsule Endoscopy, Then Standard Colonoscopy
n=328 Participants
Capsule endoscopy was ingested following colon preparation without colon insufflation or sedation.The purpose was to detect patients with polyps equal or larger than 6mm. Patients subsequently had standard colonoscopy as "gold standard" comparison.
Age, Categorical
<=18 years
0 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
227 Participants
n=99 Participants
Age, Categorical
>=65 years
101 Participants
n=99 Participants
Age, Continuous
58.5 years
STANDARD_DEVIATION 12.1 • n=99 Participants
Sex: Female, Male
Female
147 Participants
n=99 Participants
Sex: Female, Male
Male
181 Participants
n=99 Participants
Region of Enrollment
France
96 participants
n=99 Participants
Region of Enrollment
Spain
63 participants
n=99 Participants
Region of Enrollment
Germany
49 participants
n=99 Participants
Region of Enrollment
Italy
53 participants
n=99 Participants
Region of Enrollment
United Kingdom
20 participants
n=99 Participants
Region of Enrollment
Belgium
47 participants
n=99 Participants

PRIMARY outcome

Timeframe: 1 day

The number of participants that completed the capsule endoscopy procedure with video images of the entire colon that could be read by a clinician, or subsequently had a full colonoscopy with visualization by a different clinician. The number of successful procedures of each type are reported.

Outcome measures

Outcome measures
Measure
PillCam COLON
n=328 Participants
Ingestible capsule equipped with an endoscope with two imagers, given after bowel preparation and before standard colonoscopy.
Standard Colonoscopy
n=328 Participants
After bowel preparation and capsule endoscopy, patients subsequently had standard colonoscopy as "gold standard" comparison (with colon insufflation and sedation).
Number of Participants With Successful Capsule Endoscopies or Standard Colonoscopies
322 participants
326 participants

PRIMARY outcome

Timeframe: 1 day

Population: Participants in the Accuracy Analysis successfully had both capsule endoscopy and colonoscopy.

Since the standard colonoscopy is the "gold standard" to which the PillCam is to be compared, the number of participants with the indicated lesions identified by a trained clinician using standard colonoscopy procedures is reported here. Note that some Participants had multiple lesions and so could be included in more than one size category. Advanced adenoma is defined as 1) an adenoma 1 cm or larger or 2) an adenoma with villous features or high-grade dysplasia. All colorectal cancers were 6mm or larger.

Outcome measures

Outcome measures
Measure
PillCam COLON
n=320 Participants
Ingestible capsule equipped with an endoscope with two imagers, given after bowel preparation and before standard colonoscopy.
Standard Colonoscopy
After bowel preparation and capsule endoscopy, patients subsequently had standard colonoscopy as "gold standard" comparison (with colon insufflation and sedation).
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Polyp, Any Size
212 participants
Interval 66.0 to 77.0
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Polyp, < 6 mm
188 participants
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Polyp, >= 6 mm
87 participants
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Polyp, >= 10 mm
50 participants
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Adenoma, >= 6 mm
71 participants
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Adenoma, >= 10 mm
45 participants
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Advanced Adenoma, Any Size
52 participants
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Advanced Adenoma, >= 6 mm
49 participants
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Advanced Adenoma, >= 10 mm
45 participants
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Colorectal Cancer
19 participants

PRIMARY outcome

Timeframe: 1 day

Population: Accuracy Analysis population had both successful capsule endoscopy and colonoscopy.

Readings of videos from the PillCam COLON were performed by trained physicians who identified lesions (types and sizes). Sensitivity was calculated as the percentage of participants who had positive findings on capsule endoscopy (of a specified category) among those participants who had positive findings on colonoscopy of the same category (reported in Outcome Measure 1). The false negative rate is equal to 1 - sensitivity and indicated the percentage of lesions missed by capsule endoscopy.

Outcome measures

Outcome measures
Measure
PillCam COLON
n=320 Participants
Ingestible capsule equipped with an endoscope with two imagers, given after bowel preparation and before standard colonoscopy.
Standard Colonoscopy
After bowel preparation and capsule endoscopy, patients subsequently had standard colonoscopy as "gold standard" comparison (with colon insufflation and sedation).
Sensitivity of Capsule Endoscopy for Indicated Lesions
Polyp, Any Size (n=212)
72 Percentage of Participants
Interval 68.0 to 75.0
Sensitivity of Capsule Endoscopy for Indicated Lesions
Polyp, < 6 mm (n=188)
61 Percentage of Participants
Interval 57.0 to 64.0
Sensitivity of Capsule Endoscopy for Indicated Lesions
Polyp, >= 6 mm (n=87)
64 Percentage of Participants
Interval 59.0 to 72.0
Sensitivity of Capsule Endoscopy for Indicated Lesions
Polyp, >= 10 mm (n=50)
60 Percentage of Participants
Interval 51.0 to 66.0
Sensitivity of Capsule Endoscopy for Indicated Lesions
Adenoma, >= 6 mm (n=71)
68 Percentage of Participants
Interval 58.0 to 76.0
Sensitivity of Capsule Endoscopy for Indicated Lesions
Adenoma, >= 10 mm (n=45)
64 Percentage of Participants
Interval 54.0 to 72.0
Sensitivity of Capsule Endoscopy for Indicated Lesions
Advanced Adenoma, Any Size (n=52)
85 Percentage of Participants
Interval 73.0 to 93.0
Sensitivity of Capsule Endoscopy for Indicated Lesions
Advanced Adenoma, >= 6 mm (n=49)
73 Percentage of Participants
Interval 61.0 to 83.0
Sensitivity of Capsule Endoscopy for Indicated Lesions
Advanced Adenoma, >= 10 mm (n=45)
64 Percentage of Participants
Interval 54.0 to 72.0
Sensitivity of Capsule Endoscopy for Indicated Lesions
Colorectal Cancer (n=19)
74 Percentage of Participants
Interval 52.0 to 88.0

PRIMARY outcome

Timeframe: 1 day

Population: Accuracy Analysis population had both successful capsule endoscopy and colonoscopy.

Readings of videos from the PillCam COLON were performed by trained physicians who identified lesions (types and sizes). Specificity was calculated as the percentage of participants who had negative findings on capsule endoscopy (of a specified category) among participants with negative colonoscopy findings of the same category (reported in Outcome Measure 1). This corresponds to 1 - the false positive rate.

Outcome measures

Outcome measures
Measure
PillCam COLON
n=320 Participants
Ingestible capsule equipped with an endoscope with two imagers, given after bowel preparation and before standard colonoscopy.
Standard Colonoscopy
After bowel preparation and capsule endoscopy, patients subsequently had standard colonoscopy as "gold standard" comparison (with colon insufflation and sedation).
Specificity of Capsule Endoscopy for Indicated Lesions
Polyp, Any Size (n=108)
78 Percentage of Participants
Interval 71.0 to 84.0
Specificity of Capsule Endoscopy for Indicated Lesions
Polyp, < 6 mm (n=132)
82 Percentage of Participants
Interval 76.0 to 87.0
Specificity of Capsule Endoscopy for Indicated Lesions
Polyp, >= 6 mm (n=233)
84 Percentage of Participants
Interval 81.0 to 87.0
Specificity of Capsule Endoscopy for Indicated Lesions
Polyp, >= 10 mm (n=270)
98 Percentage of Participants
Interval 96.0 to 99.0
Specificity of Capsule Endoscopy for Indicated Lesions
Adenoma, >= 6 mm (n=249)
82 Percentage of Participants
Interval 79.0 to 84.0
Specificity of Capsule Endoscopy for Indicated Lesions
Adenoma, >= 10 mm (n=275)
97 Percentage of Participants
Interval 96.0 to 99.0
Specificity of Capsule Endoscopy for Indicated Lesions
Advanced Adenoma, Any Size (n=268)
50 Percentage of Participants
Interval 48.0 to 51.0
Specificity of Capsule Endoscopy for Indicated Lesions
Advanced Adenoma, >= 6 mm (n=271)
79 Percentage of Participants
Interval 77.0 to 81.0
Specificity of Capsule Endoscopy for Indicated Lesions
Advanced Adenoma, >= 10 mm (n=275)
97 Percentage of Participants
Interval 96.0 to 99.0
Specificity of Capsule Endoscopy for Indicated Lesions
Colorectal Cancer (n=301)
74 Percentage of Participants
Interval 72.0 to 75.0

SECONDARY outcome

Timeframe: 1 day

Overall colon cleanliness was judged for capsule endoscopy and colonoscopy on a four-point grading index scale as follows: 1. poor cleansing level (Large amount of fecal residue.) 2. fair cleansing level (Enough feces or dark fluid present to preclude a completely reliable examination.) 3. good cleansing level (Small amount of feces or dark fluid, but not enough to interfere with examination.) 4. excellent cleansing level (No more than small bits of adherent feces.)

Outcome measures

Outcome measures
Measure
PillCam COLON
n=320 Participants
Ingestible capsule equipped with an endoscope with two imagers, given after bowel preparation and before standard colonoscopy.
Standard Colonoscopy
n=320 Participants
After bowel preparation and capsule endoscopy, patients subsequently had standard colonoscopy as "gold standard" comparison (with colon insufflation and sedation).
Percent of Participants With Scoring Index 3 or 4
72 Percentage of Participants
Interval 66.0 to 77.0
87 Percentage of Participants
Interval 83.0 to 91.0

SECONDARY outcome

Timeframe: Within 7 days

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: within 7 days

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Within 7 days

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: within 7 days

Outcome measures

Outcome data not reported

Adverse Events

Adverse Events Related to Colonoscopy

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Adverse Events Related to the Capsule

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Hila Debby

Given Imaging

Phone: +972 4 9097774

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place